Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in aids
- 1 September 1995
- journal article
- clinical trial
- Published by Elsevier in International Journal of Immunopharmacology
- Vol. 17 (9), 719-727
- https://doi.org/10.1016/0192-0561(95)00060-f
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Dose-dependent opposite effect of zinc on apoptosis in mouse thymocytesInternational Journal of Immunopharmacology, 1995
- Reversibility of the thymic involution and of age-related peripheral immune dysfunctions by zinc supplementation in old miceInternational Journal of Immunopharmacology, 1995
- Role of the Low Zinc Bioavailability on Cellular Immune Effectiveness in Cystic FibrosisClinical Immunology and Immunopathology, 1995
- Neuroendocrine‐Immune Aging: an Integrative View on the Role of ZincAnnals of the New York Academy of Sciences, 1994
- Programmed Death of T Cells in HIV-1 InfectionScience, 1992
- The role of tumour necrosis factor‐α in acquired immunodeficiency syndromeJournal of Internal Medicine, 1990
- Infection and immunity in Down syndrome: A trial of long-term low oral doses of zincThe Journal of Pediatrics, 1989
- Purified blood monocytes from HIV 1-infected patients induce high levels of TNFα and IL-1Clinical Immunology and Immunopathology, 1989
- Serum thymulin in human zinc deficiency.JCI Insight, 1988
- Patients at Risk for AIDS-Related Opportunistic InfectionsNew England Journal of Medicine, 1985